Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)
|
June 11, 2002
Bexxar (Corixa/GlaxoSmithKline)
Bruce Cheson
Future Oncology (London, England)
|
December 23, 2010
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial
Chaitra Ujjani, Bruce Cheson
Blood and Lymphatic Cancer : Targets and Therapy
|
August 6, 2021
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Georgios Pongas, Bruce Cheson
Therapeutic Advances in Hematology
|
April 8, 2016
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
Kruti Sheth Nair, Bruce Cheson
Expert Review of Hematology
|
August 25, 2018
Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma
Mayur Narkhede, Maryam Sarraf Yazdy, Bruce Cheson
International Journal of Clinical and Experimental Pathology
|
November 18, 2009
Asymptomatic diffuse "encephalitic" cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature
Malak Abedalthagafi, Elisabeth J Rushing, David Garvin, et al.
Clinical Immunology (Orlando, Fla.)
|
June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
Carla Casulo, Julie M Vose, William Y Ho, et al.
Blood
|
October 15, 2005
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
Jacques-Louis Binet, Federico Caligaris-Cappio, Daniel Catovsky, et al.
Cancer Immunology Research
|
June 25, 2014
CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells
Juan Du, Sandra Lopez-Verges, Brandelyn N Pitcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
Ann S LaCasce, Travis Dockter, Amy S Ruppert, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Current Opinion in Investigational Drugs (London, England : 2000)
|
June 11, 2002
Bexxar (Corixa/GlaxoSmithKline)
Bruce Cheson
Future Oncology (London, England)
|
December 23, 2010
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial
Chaitra Ujjani, Bruce Cheson
Blood and Lymphatic Cancer : Targets and Therapy
|
August 6, 2021
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Georgios Pongas, Bruce Cheson
Therapeutic Advances in Hematology
|
April 8, 2016
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
Kruti Sheth Nair, Bruce Cheson
Expert Review of Hematology
|
August 25, 2018
Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma
Mayur Narkhede, Maryam Sarraf Yazdy, Bruce Cheson
International Journal of Clinical and Experimental Pathology
|
November 18, 2009
Asymptomatic diffuse "encephalitic" cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature
Malak Abedalthagafi, Elisabeth J Rushing, David Garvin, et al.
Clinical Immunology (Orlando, Fla.)
|
June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
Carla Casulo, Julie M Vose, William Y Ho, et al.
Blood
|
October 15, 2005
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
Jacques-Louis Binet, Federico Caligaris-Cappio, Daniel Catovsky, et al.
Cancer Immunology Research
|
June 25, 2014
CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells
Juan Du, Sandra Lopez-Verges, Brandelyn N Pitcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
Ann S LaCasce, Travis Dockter, Amy S Ruppert, et al.
Page
of 2